Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Merit Financial Group LLC

Merit Financial Group LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 123.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,232 shares of the biopharmaceutical company’s stock after buying an additional 2,342 shares during the quarter. Merit Financial Group LLC’s holdings in Alnylam Pharmaceuticals were worth $1,930,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ALNY. Root Financial Partners LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $25,000. Salomon & Ludwin LLC purchased a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $27,000. ORG Partners LLC increased its position in Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 33 shares during the last quarter. Quent Capital LLC purchased a new position in Alnylam Pharmaceuticals during the third quarter worth approximately $39,000. Finally, Hilltop National Bank acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $41,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $332.61 on Wednesday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The firm has a market cap of $44.11 billion, a price-to-earnings ratio of 194.51 and a beta of 0.35. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The company has a fifty day simple moving average of $371.01 and a 200 day simple moving average of $424.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). The firm had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business’s quarterly revenue was up 84.9% on a year-over-year basis. During the same period in the previous year, the company earned ($0.65) earnings per share. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,959 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $607,446.72. Following the sale, the executive vice president directly owned 31,769 shares in the company, valued at $9,850,931.52. The trade was a 5.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Pushkal Garg sold 2,242 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $695,199.36. Following the transaction, the executive vice president owned 24,848 shares of the company’s stock, valued at approximately $7,704,867.84. This trade represents a 8.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 36,578 shares of company stock valued at $12,416,105 in the last three months. 1.20% of the stock is currently owned by company insiders.

Trending Headlines about Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $429 and reaffirmed a “buy” rating, citing upside vs. the current price (Canaccord’s note implies meaningful upside). Canaccord price-target raise
• Positive Sentiment: A MarketBeat-linked Motley Fool piece reports a pundit upgrade that helped lift sentiment and trading interest in ALNY. Why Alnylam Was Soaring
• Positive Sentiment: A bullish roundup in The Globe and Mail highlighted Alnylam among favorable healthcare ideas, supporting broader analyst-driven positivity. Analysts Are Bullish
• Neutral Sentiment: Short-interest data in the feed shows zero/NaN values and a 0.0 days-to-cover figure — likely a data/reporting artifact rather than new market pressure; treat as non-actionable until confirmed by an exchange report.
• Negative Sentiment: Multiple insider sales disclosed this week could weigh on sentiment: CEO Yvonne Greenstreet sold 6,958 shares at ~$310; several EVPs (Jeffrey Poulton, Kevin Fitzgerald, Tolga Tanguler, Pushkal Garg) sold mid‑hundreds to low‑thousands of shares at ~$310–332. These trades reduced insiders’ stakes by mid-single-digit percentages. Filings: SEC links for the disclosures. Yvonne Greenstreet SEC filing Jeffrey Poulton SEC filing Kevin Fitzgerald filings Tolga Tanguler SEC filing Pushkal Garg SEC filing
• Negative Sentiment: Chardan Capital trimmed its price target to $425 (from a higher prior target), a modest negative datapoint that partly offsets other analyst optimism. Chardan target cut

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ALNY. HC Wainwright cut their target price on Alnylam Pharmaceuticals from $570.00 to $510.00 and set a “buy” rating on the stock in a research report on Friday, January 30th. Leerink Partners dropped their price target on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research note on Monday, December 15th. Oppenheimer initiated coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price objective on the stock. Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Finally, Truist Financial cut their price target on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Twenty-two investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $477.96.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.